Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07650838 | OVV-01 Injection Combined With AK112 Injection for the Treatment of Patients With Advanced Soft Tissue Sarcoma (STS) | not yet recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 16, 2026 | clinicaltrials |
| NCT07651007 | Short-course RT Followed by NALIRIFOX Plus Pucotenlimab as Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer With MSS/pMMR | not yet recruiting | Phase 2 | 29 | Wang XinOTHER | 0 | Jun 16, 2026 |
| clinicaltrials |
| NCT07651618 | A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma(PERTIL-01) | not yet recruiting | Phase 2 | 10 | East Metropolitan Health Service, AustraliaOTHER_GOV | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07612787 | A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma(BELAMI) | not yet recruiting | Phase 1 / Phase 2 | 44 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07647068 | Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors | not yet recruiting | Phase 2 | 59 | Joal BeaneOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07647432 | HEME-25: Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV(HEME-25) | not yet recruiting | Phase 2 / Phase 3 | 17 | University of Illinois at ChicagoOTHER | 0 | Jun 15, 2026 | clinicaltrials |
| NCT07647653 | Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian Cancer | not yet recruiting | Phase 2 | 120 | Shandong UniversityOTHER | 0 | Jun 15, 2026 | clinicaltrials |
| NCT07358689 | Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 120 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07612007 | HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization | not yet recruiting | Phase 2 | 80 | Mayo ClinicOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07644208 | PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatocellular Carcinoma After Curative Hepatectomy | not yet recruiting | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 0 | Jun 12, 2026 | clinicaltrials |
| NCT07645118 | Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer(IMPERIA) | not yet recruiting | Phase 2 | 10 | Dr. Te VuongOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07102940 | Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer | not yet recruiting | Phase 2 | 50 | George Washington UniversityOTHER | 0 | Jun 11, 2026 | clinicaltrials |
| NCT07560475 | Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients | not yet recruiting | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07618923 | Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast Cancer(TD-DASHER-01) | not yet recruiting | Phase 2 | 20 | Tang-Du HospitalOTHER | 0 | Jun 11, 2026 | clinicaltrials |
| NCT07641010 | PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma | not yet recruiting | Phase 1 / Phase 2 | 112 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07642453 | VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia. | not yet recruiting | Phase 2 | 110 | Hematology department of the 920th hospitalOTHER | 0 | Jun 11, 2026 | clinicaltrials |
| NCT07643428 | Cancer Lipidome Adaptation and Resculping Through Omega-3 PUFAs in Breast Tumors(CLARA) | not yet recruiting | Phase 2 | 35 | Medical College of WisconsinOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07643584 | De-Escalation of Axillary Management in Advanced Nodal Disease(DEMAND) | not yet recruiting | Phase 2 | 120 | University of Kansas Medical CenterOTHER | 0 | Jun 11, 2026 | clinicaltrials |
| NCT07441837 | Terbium 161 PSMA in Lutetium-177 PSMA Naive Patients(TeLuNa) | not yet recruiting | Phase 2 | 60 | Ankara UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07535905 | Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients(REVIVE) | not yet recruiting | Phase 2 | 96 | University Health Network, TorontoOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07575412 | SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS | not yet recruiting | Phase 2 | 180 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07638501 | Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer | not yet recruiting | Phase 2 | 123 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07638631 | Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer(DIAMC-GC) | not yet recruiting | Phase 2 | 30 | Chen LizhuOTHER_GOV | 0 | Jun 10, 2026 | clinicaltrials |
| NCT07639983 | Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma | not yet recruiting | Phase 2 | 44 | Sheng TaiOTHER | 0 | Jun 10, 2026 | clinicaltrials |
| NCT07146230 | The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2(SPRINT 2) | not yet recruiting | Phase 2 | 52 | Montefiore Medical CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07303283 | Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 140 | Kai HuOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07634601 | Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer | not yet recruiting | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07635524 | A Phase 2 Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT. | not yet recruiting | Phase 2 | 34 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07636226 | QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 120 | Sun Yat-sen UniversityOTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07636564 | Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment | not yet recruiting | Phase 2 | 90 | SWOG Cancer Research NetworkNETWORK | 0 | Jun 9, 2026 | clinicaltrials |
| NCT07636772 | A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma | not yet recruiting | Phase 2 | 132 | AkesoINDUSTRY | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | not yet recruiting | Phase 2 | 227 | GV20 TherapeuticsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07631871 | An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy | not yet recruiting | Phase 2 | 10 | Haihua YuanOTHER | 0 | Jun 8, 2026 | clinicaltrials |
| NCT07631884 | Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor | not yet recruiting | Phase 2 | 15 | Haihua YuanOTHER | 0 | Jun 8, 2026 | clinicaltrials |
| NCT07632209 | Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment(Aurora003) | not yet recruiting | Phase 2 | 46 | Yayi HeOTHER | 0 | Jun 8, 2026 | clinicaltrials |
| NCT07634094 | Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer | not yet recruiting | Phase 2 | 28 | Kalinski, Pawel, MD, PhDOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07630077 | Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities | not yet recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07630103 | Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer | not yet recruiting | Phase 2 | 100 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07630363 | PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC | not yet recruiting | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06476704 | Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas(PRACTISS) | not yet recruiting | Phase 2 | 42 | Centre Paul StraussOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07218575 | Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations | not yet recruiting | Phase 2 / Phase 3 | 60 | Boston Children's HospitalOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07234877 | Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets | not yet recruiting | Phase 2 | 158 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Jun 4, 2026 | clinicaltrials |
| NCT07626021 | Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms | not yet recruiting | Phase 2 | 15 | Zhongshan Hospital (Xiamen), Fudan UniversityOTHER | 0 | Jun 4, 2026 | clinicaltrials |
| NCT07627321 | Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer(PRAD2) | not yet recruiting | Phase 2 | 39 | Anhui Provincial Cancer HospitalOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07627464 | Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy(ALTER-UC-011) | not yet recruiting | Phase 2 | 144 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07627620 | Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer | not yet recruiting | Phase 2 | 54 | Hunan Cancer HospitalOTHER | 0 | Jun 4, 2026 | clinicaltrials |
| NCT07628062 | Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation | not yet recruiting | Phase 2 | 70 | ImmunityBio, Inc.INDUSTRY | 0 | Jun 4, 2026 | clinicaltrials |
| NCT07622225 | SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 264 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Jun 3, 2026 | clinicaltrials |
| NCT07622550 | A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance | not yet recruiting | Phase 2 | 80 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07622706 | Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma | not yet recruiting | Phase 2 | 60 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jun 3, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jun 16, 2026source: clinicaltrials